References
- Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295–e307. doi: 10.1016/S2352-3018(23)00028-0
- Popping S, Kall M, Nichols BE, et al. Quality of life among people living with HIV in England and the Netherlands: a population-based study. Lancet Reg Health Eur. 2021;8:100177. doi: 10.1016/j.lanepe.2021.100177
- Gu SX, Zhu YY, Wang C, et al. Recent discoveries in HIV-1 reverse transcriptase inhibitors. Curr Opin Pharmacol. 2020;54:166–172. doi: 10.1016/j.coph.2020.09.017
- Linder A, Bauernfried S, Cheng Y, et al. CARD8 inflammasome activation triggers pyroptosis in human T cells. Embo J. 2020;39(19):e105071. doi: 10.15252/embj.2020105071
- Johnson DC, Taabazuing CY, Okondo MC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24(8):1151–1156. doi: 10.1038/s41591-018-0082-y
- Hsiao JC, Neugroschl AR, Chui AJ, et al. A ubiquitin-independent proteasome pathway controls activation of the CARD8 inflammasome. J Biol Chem. 2022;298(7):102032. doi: 10.1016/j.jbc.2022.102032
- Wang Q, Gao H, Clark KM, et al. CARD8 is an inflammasome sensor for HIV-1 protease activity. Science. 2021;371(6535):eabe1707. doi :10.1126/science.abe1707.
- Wang Q, Clark KM, Tiwari R, et al. The CARD8 inflammasome dictates HIV/SIV pathogenesis and disease progression. Cell. 2024;187(5):1223–1237.e16. doi: 10.1016/j.cell.2024.01.048
- Harrison JJEK, Passos DO, Bruhn JF, et al. Cryo-EM structure of the HIV-1 Pol polyprotein provides insights into virion maturation. Sci Adv. 2022;8(27):eabn9874. doi: 10.1126/sciadv.abn9874.
- Hussein M, Molina MA, Berkhout B, et al. A CRISPR-Cas cure for HIV/AIDS. Int J Mol Sci. [2023 Jan 13];24(2):1563. doi: 10.3390/ijms24021563
- Wang G, Zhao N, Berkhout B, et al. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther. 2016;24(3):522–526. doi: 10.1038/mt.2016.24
- Okee M, Bayiyana A, Musubika C, et al. In vitro transduction and target-mutagenesis efficiency of HIV-1 pol gene targeting ZFN and CRISPR/Cas9 delivered by various plasmids and/or vectors: toward an HIV Cure. AIDS Res Hum Retroviruses. 2018;34(1):88–102. doi: 10.1089/aid.2017.0234
- Yin L, Zhao F, Sun H, et al. CRISPR-Cas13a inhibits HIV-1 infection. Mol Ther Nucleic Acids. 2020;21:147–155. doi: 10.1016/j.omtn.2020.05.030
- Nguyen H, Wilson H, Jayakumar S, et al. Efficient inhibition of HIV Using CRISPR/Cas13d Nuclease System. Viruses. 2021;13:1850. doi: 10.3390/v13091850
- Borthwick N, Ahmed T, Ondondo, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22(2):464–475. doi: 10.1038/mt.2013.248
- Mothe B, Llano A, Ibarrondo J, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med. 2011;9(1):208. doi: 10.1186/1479-5876-9-208
- Ojwach DBA, Madlala P, Gordon M, et al. Vulnerable targets in HIV-1 pol for attenuation-based vaccine design. Virology. 2021;554:1–8. doi: 10.1016/j.virol.2020.12.003
- Moyo N, Vogel AB, Buus S, et al. Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA. Mol Ther Methods Clin Dev. 2018;12:32–46. doi: 10.1016/j.omtm.2018.10.010
- Hudgens MG, Gilbert PB, Mascola JR, et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis. 2009;200(4):609–613. doi: 10.1086/600891